OCEL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Mar 2024 @ 15:14):

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases...

Stats
Today's Volume	4 735.00
Average Volume	4 716.00
Market Cap	19.97M
EPS	$-0.00114 ( 2023-07-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.567
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-29	Leider Harry L.	Buy	500 000	Common Stock
2023-06-28	Leider Harry L.	Buy	549 450	Common Stock
2023-12-19	Leider Harry L.	Sell	5 248	Common Stock
2023-07-07	Skycrest Holdings, Llc	Buy	320 710	Common Stock
2023-06-29	Skycrest Holdings, Llc	Buy	200 000	Common Stock

INSIDER POWER
-77.13
Last 93 transactions
Buy: 116 969 610 \| Sell: 385 387 546

Organicell Regenerative Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Organicell Regenerative Financials

Annual	2023
Revenue:	$4.56M
Gross Profit:	$4.05M (88.86 %)
EPS:	$-0.990

Q4	2023
Revenue:	$1.42M
Gross Profit:	$1.29M (90.65 %)
EPS:	$-0.150

Q3	2023
Revenue:	$1.22M
Gross Profit:	$1.06M (86.70 %)
EPS:	$-0.230

Q2	2023
Revenue:	$845 501
Gross Profit:	$737 425 (87.22 %)
EPS:	$-0.280

Financial Reports:

No articles found.

Organicell Regenerative

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.